These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 26331432)
21. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001 [TBL] [Abstract][Full Text] [Related]
22. Spotlight on lenalidomide in relapsed or refractory multiple myeloma. Scott LJ; Lyseng-Williamson KA BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918 [TBL] [Abstract][Full Text] [Related]
23. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679 [TBL] [Abstract][Full Text] [Related]
24. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma. Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305 [No Abstract] [Full Text] [Related]
25. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348 [TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
27. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915 [TBL] [Abstract][Full Text] [Related]
28. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076 [TBL] [Abstract][Full Text] [Related]
29. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Kneppers E; Lokhorst HM; Eeltink CM; Huls G; Kersten MJ; Koedam J; Minnema MC; van Oers MH; Raymakers RA; Schaafsma MR; Vellenga E; Wijermans PW; Wittebol S; Sonneveld P; Zweegman S Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):138-43. PubMed ID: 20371448 [TBL] [Abstract][Full Text] [Related]
30. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. San-Miguel JF; Dimopoulos MA; Stadtmauer EA; Rajkumar SV; Siegel D; Bravo ML; Olesnyckyj M; Knight RD; Zeldis JB; Harousseau JL; Weber DM Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):38-43. PubMed ID: 21273172 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Berdeja JG; Bauer T; Arrowsmith E; Essell J; Murphy P; Reeves JA; Boccia RV; Donnellan W; Flinn I Br J Haematol; 2017 Apr; 177(2):254-262. PubMed ID: 28169430 [TBL] [Abstract][Full Text] [Related]
32. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491 [TBL] [Abstract][Full Text] [Related]
33. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206 [TBL] [Abstract][Full Text] [Related]
34. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921 [TBL] [Abstract][Full Text] [Related]